Omeprazole Suspension (Various Strengths)

Oral suspension: Shake well immediately before each dose. Administer 30–60 minutes before the first meal of the day for maximum efficacy, as omeprazole acts on actively secreting proton pumps stimulated by food. Use the oral syringe or measuring device provided. For nasogastric or orogastric tube administration, confirm compatibility with tubing and flush the line before and after dosing. Do not administer via tube without pharmacist guidance on dilution or delivery technique.

Dosing is weight-based for pediatric patients and diagnosis-dependent; all regimens must be prescribed by the treating clinician.

• Neonates/Infants: Typically 0.5–1.5 mg/kg/day in one or two divided doses — prescriber-determined based on weight and clinical response.
• Pediatric (1–16 years, GERD/EE): 10–20 mg/day (weight-based); refer to FDA label for pediatric dosing tables.
• Adults (GERD/maintenance): 20 mg once daily; erosive esophagitis healing typically 20–40 mg/day for 4–8 weeks.
• H. pylori eradication: 20 mg twice daily as part of a triple or quadruple regimen per current guidelines.
• Final strength, dose, and duration are determined by the prescriber.

• Omeprazole: A substituted benzimidazole prodrug activated by acid-catalyzed conversion in the secretory canaliculus of gastric parietal cells. The active sulfenamide metabolite forms covalent disulfide bonds with cysteine residues on the luminal surface of H+/K+-ATPase (the proton pump), irreversibly inhibiting acid secretion. Recovery of acid secretion requires synthesis of new enzyme protein, giving PPI effects a duration longer than the short plasma half-life (~1 hour) would suggest. Omeprazole is a racemic mixture; it undergoes significant first-pass hepatic metabolism via CYP2C19 and CYP3A4.

Indications context: Compounded omeprazole suspension is used most commonly in neonatal and pediatric GERD, erosive esophagitis, and acid peptic disorders where solid oral forms are impractical; it is also used in adult patients with dysphagia, feeding tube dependence, or specific strength requirements. Off-label use in neonatal necrotizing enterocolitis prophylaxis and stress ulcer prophylaxis has been described.

Prescriber monitoring considerations:

• Symptom reassessment at 4–8 weeks; avoid long-term use at highest effective dose without periodic indication review.
• Serum magnesium baseline and periodic monitoring with prolonged use (especially >12 months); supplement if hypomagnesemia develops.
• Bone mineral density monitoring in patients on chronic high-dose PPI therapy.
• Vitamin B12 and iron levels in patients on long-term therapy, particularly elderly or those with dietary restrictions.
• Reassess for C. difficile in patients on PPI therapy who develop new-onset diarrhea.
• Review for drug interactions at initiation, particularly clopidogrel, HIV antiretrovirals, and methotrexate.

Contraindications:

• Hypersensitivity to omeprazole, other PPIs, or any formulation excipient
• Concurrent use with rilpivirine-containing HIV regimens (significantly reduces rilpivirine efficacy)
• Hypersensitivity to substituted benzimidazoles (cross-reactivity possible within PPI class)

Warnings & Precautions:

• Hypomagnesemia: may occur with prolonged use (>3 months); monitor serum magnesium in high-risk patients
• Fracture risk: long-term, high-dose PPI use associated with increased risk of hip, wrist, and spine fractures
• C. difficile infection: acid suppression may increase susceptibility; consider in patients with unexplained diarrhea
• Lupus erythematosus (subacute cutaneous): reported with PPI use; discontinue if occurs

Drug Interactions:

• Clopidogrel: omeprazole inhibits CYP2C19 and reduces clopidogrel activation — may increase cardiovascular risk; consider alternative PPI if clinically significant
• Methotrexate: PPI may increase methotrexate toxicity via reduced renal clearance
• Atazanavir, rilpivirine: acid suppression reduces bioavailability — contraindicated or not recommended
• Iron, calcium, vitamin B12: reduced absorption with chronic acid suppression

Common Side Effects: Headache, diarrhea, nausea, abdominal pain, flatulence, and constipation.

Compounded omeprazole suspensions in sodium bicarbonate (alkaline buffer) should be stored refrigerated at 2–8°C if specified by the dispensing pharmacy, or at room temperature if formulated for room-temperature stability — follow the label. Shake well before each use. Beyond-use date is typically 30 days refrigerated for bicarbonate-based suspensions. Do not freeze. Keep out of reach of children. Discard any unused suspension after the beyond-use date.

Why is my child being given a liquid form of omeprazole instead of the tablet?

Infants and young children cannot swallow tablets or capsules. Compounded omeprazole suspension provides an accurately measured liquid dose appropriate for their weight and developmental stage. Commercial liquid formulations of omeprazole are not currently available in the US, making compounding the clinical standard for this population.

Should I give this before or after feeding?

For optimal efficacy, administer 30–60 minutes before a feed or meal, as omeprazole targets active proton pumps that are stimulated by food intake. Your prescriber or pharmacist will specify timing on the prescription label.

How long can this suspension be stored?

The beyond-use date is assigned by Genesis Compounding and appears on the label. Bicarbonate-buffered omeprazole suspensions typically have a 30-day refrigerated shelf life. Discard any remaining medication after that date.

Does long-term PPI use cause problems?

Long-term use (months to years) has been associated with decreased magnesium absorption, reduced vitamin B12 and iron absorption, a modest increase in fracture risk, and susceptibility to C. difficile infection. Your prescriber will monitor for these effects and reassess the need for ongoing therapy regularly.

Is this FDA-approved?

Omeprazole is FDA-approved in capsule, delayed-release tablet, and powder-for-oral-suspension (Zegerid OTC) forms. This specific compounded liquid suspension is a prescriber-directed, patient-specific 503A preparation not FDA-approved as a compounded product.